Atopic Dermatitis Clinical Trials in Northridge, California

6 studies are recruiting for atopic dermatitis in Northridge, California right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. A Study to Learn About Study Medicine Called PF-08049820 in People With Eczema

   The purpose of this study is to learn if the study medicine (PF-08049820) is safe and effective for the treatment of atopic dermatitis (AD), also known as eczema, or atopic eczema. People with this condition may have severe itching and rashes on the skin. The study is seeking participants who: 1. A…

   Stage

   Phase 2

   Ages

   18 to 64

   Site

   Northridge Clinical Trials, Northridge, California

   Locations

   23 in total

   Run by

   Pfizer

   See if you can join NCT07216027 on ClinicalTrials.gov

2. A Study to Learn About the Study Medicine Called Tilrekimig in People With Moderate-to-Severe Eczema

   The purpose of this study is to find out how well tilrekimig works, how safe it is, and how it affects the body when used together with medicated creams or ointments in adults and adolescents with moderate to severe atopic dermatitis (eczema). Eczema (also called atopic dermatitis) is a common skin…

   Stage

   Phase 3

   Ages

   12 and older

   Site

   Northridge Clinical Trials, Northridge, California

   Locations

   3 in total

   Run by

   Pfizer

   See if you can join NCT07765888 on ClinicalTrials.gov

3. A Phase 2b Study of the Effects of Camoteskimab in Adults With Moderate-to-Severe Atopic Dermatitis

   This is a phase 2b, multicenter, randomized, double-blind, placebo-controlled study.

   Stage

   Phase 2

   Ages

   18 to 65

   Site

   Northridge Clinical Trials, Northridge, California

   Locations

   85 in total

   Run by

   Apollo Therapeutics Ltd

   See if you can join NCT07599813 on ClinicalTrials.gov

4. This Study is a Non-interventional Disease Registry of Adolescent and Adult Patients With Atopic Dermatitis Who Initiate or Switch Any Systemic Treatment

   The objectives of this prospective non-interventional study are to characterize the existing unmet needs across the spectrum of atopic dermatitis (AD), enhance the understanding of the patient journey, and evaluate the safety and clinical outcomes of systemic AD treatments in a real-world setting. …

   Stage

   Not phased

   Ages

   12 and older

   Site

   Northridge Clinical Trials, LLC- Site Number : 8400009, Northridge, California

   Locations

   79 in total

   Run by

   Sanofi

   See if you can join NCT07290803 on ClinicalTrials.gov

5. A Phase 2b Dose-Ranging Study to Evaluate the Efficacy and Safety of ENV-294 in Adults With Moderate-to-Severe Atopic Dermatitis

   This double-blind, placebo-controlled study is designed to evaluate the safety and efficacy of ENV-294 in adults with moderate-to-severe atopic dermatitis (AD). The study will compare three dose levels of ENV-294 with placebo administered for 12 weeks. Participants will undergo screening, receive s…

   Stage

   Phase 2

   Ages

   18 and older

   Site

   Enveda Investigative Site, Northridge, California

   Locations

   9 in total

   Run by

   Enveda Therapeutics

   See if you can join NCT07643766 on ClinicalTrials.gov

6. A Study To Learn About Two Study Medicines (PF-07275315 And PF-07264660) In People Who Have Moderate To Severe Atopic Dermatitis

   The purpose of this study is to learn about the safety and effects of 2 study medicines (PF-07275315 and PF-07264660) for the treatment of atopic dermatitis (AD). AD is a long- lasting itchy red rash, caused by a skin reaction. This study is seeking participants who: * are 18 years of age or more. …

   Stage

   Phase 2

   Ages

   18 and older

   Site

   Northridge Clinical Trials, Northridge, California

   Locations

   98 in total

   Run by

   Pfizer

   See if you can join NCT05995964 on ClinicalTrials.gov